We may earn a commission when readers sign up through partner links. Rankings reflect our published methodology, not advertiser fees.
Ranked #9

PlushCare

General primary-care telehealth with GLP-1 prescribing — broad practice scope, less weight-management specialization

69 / 100
★★★★☆
3.8

What PlushCare Does Right

PlushCare is a general primary-care telehealth platform that offers GLP-1 prescribing as part of its broader practice. PlushCare's clinical bench is exclusively MD and DO (no NPs), which is a structural strength versus telehealth competitors who lean more heavily on NPs. The platform has a long operating history (since 2014) and is acquired by Accolade, providing operational stability.

For patients who already use PlushCare for primary care, adding GLP-1 prescribing into the same relationship is convenient. The visit-based pricing model is more transparent than program-fee structures — you pay $99 per visit, $17/month for membership, and medication separately through your insurance or cash-pay.

Where PlushCare Could Improve

PlushCare is not a weight-management specialist platform — GLP-1 prescribing is one offering among many. Patients seeking the structured behavioral support, dose-titration coaching, and weight-management curriculum offered by Form, Sequence, or NexLife will find PlushCare's GLP-1 program comparatively bare. PlushCare focuses on brand-name FDA-approved medications and does not offer a compounded pathway, which makes it expensive for uninsured-and-uncovered patients. The visit-based pricing means follow-ups during titration are billable visits, not included in a flat fee.

Provider Snapshot

Medications
Wegovy, Zepbound, Ozempic, Mounjaro
Starting price
$99/visit + $17/mo membership
Pricing model
Visit + membership + medication
Clinician type
MD / DO
Labs
Add-on
3rd-party testing
N/A (brand-name only)
State availability
All 50 states
Certifications
BBB
Time to first Rx
1–3 business days

Pros

  • MD / DO only (no NPs)
  • All 50 states
  • Long operating history (since 2014)
  • Visit-based pricing transparency
  • Accolade parent company stability
  • Integrated with broader primary care

Cons

  • Not a weight-management specialist
  • No compounded pathway
  • Visit-based pricing accumulates with follow-ups
  • No structured behavioral support
  • No 503A/503B sourcing transparency (no compounded)
16/25Price Transparency
17/25Clinical Protocol
15/20Prescriber Access
14/20Patient Outcomes
7/10Op. Transparency
Bottom line

PlushCare is the right pick for patients who already use it for primary care and want to add GLP-1 prescribing into the same relationship. As a standalone weight-management choice, NexLife and Form are stronger.

Compare to NexLife → All providers →

How PlushCare compares

Compare PlushCare side-by-side

Frequently asked questions

How much does PlushCare cost?

PlushCare pricing ranges from $16.99/mo + $99 visit. Starting price is $99/month. Pricing details and any titration upcharges are described above in the pricing section.

Is PlushCare legitimate?

PlushCare is an established telehealth program. Good for patients with insurance who want traditional primary-care telehealth. Always verify a provider's pharmacy partnerships, prescribing physician credentials, and state availability before signing up.

Does PlushCare accept insurance?

Most direct-to-consumer compounded GLP-1 programs do not accept insurance for the medication itself. If insurance coverage matters to you, see our insurance pathway providers (Mochi Health, Ro, Form Health) and our insurance hub.

What medications does PlushCare prescribe?

PlushCare prescribes: Wegovy, Zepbound, Ozempic (off-label).

In what states is PlushCare available?

PlushCare is available in All 50 states.

Who can use PlushCare?

Eligibility is determined by an intake questionnaire and clinical review. Generally, FDA-approved weight-loss criteria are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Off-label compounded prescribing is at the discretion of the prescribing clinician.

Editorial note. By GLP Agonists Editorial · Last updated May 2026. This review is editorially independent. See our methodology and editorial disclosure. Not medical advice — always consult a licensed clinician.